Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier
- PMID: 40427617
- PMCID: PMC12109016
- DOI: 10.3390/biom15050725
Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier
Abstract
Pancreatic ductal adenocarcinoma (PDA) is a highly challenging malignancy to treat, with a high mortality rate and limited therapeutic options. Despite advances in cancer research, the prognosis for patients diagnosed with PDA is often poor due to late-stage detection and resistance to conventional therapies. Consequently, there is growing interest in the potential of bioactive compounds as alternative or adjuvant treatments, given their ability to target multiple aspects of cancer biology, offering a more holistic approach to treatment. In the context of PDA, certain bioactive compounds, such as polyphenols (found in fruits, vegetables, and tea), flavonoids, carotenoids and compounds in cruciferous vegetables, have shown potential in inhibiting cancer cell growth, reducing inflammation, and promoting cancer cell apoptosis. This review aims to elucidate the mechanisms, by which these bioactive compounds exert their effects, modulating the oxidative stress, influencing inflammatory pathways and regulating cell survival and death. It also highlights current clinical trials that are paving the way toward incorporating these natural agents into mainstream treatment strategies, with the goal of boosting the efficacy of conventional therapies for PDA.
Keywords: bioactive compounds; flavonoids; pancreatic cancer.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Therapeutical potential of natural products in treatment of pancreatic cancer: a review.Mol Biol Rep. 2025 Jan 31;52(1):179. doi: 10.1007/s11033-025-10287-8. Mol Biol Rep. 2025. PMID: 39888508 Review.
-
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.Gut. 2018 Dec;67(12):2142-2155. doi: 10.1136/gutjnl-2017-315144. Epub 2017 Oct 28. Gut. 2018. PMID: 29080858 Free PMC article.
-
Flavonoids as modulators of miRNA expression in pancreatic cancer: Pathways, Mechanisms, And Therapeutic Potential.Biomed Pharmacother. 2024 Oct;179:117347. doi: 10.1016/j.biopha.2024.117347. Epub 2024 Sep 5. Biomed Pharmacother. 2024. PMID: 39241569 Review.
-
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.Mol Cancer Ther. 2010 Sep;9(9):2582-92. doi: 10.1158/1535-7163.MCT-10-0370. Epub 2010 Jul 26. Mol Cancer Ther. 2010. PMID: 20660600 Free PMC article.
-
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways.Sci Rep. 2025 Apr 3;15(1):11376. doi: 10.1038/s41598-025-95766-5. Sci Rep. 2025. PMID: 40175514 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical